Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.

A novel tertiary amine series of potent muscarinic M(3) receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease. Geminal dimethyl functionality present in this series of compounds confers very long dissociative half-life (slow off-rate) from the M(3) receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips. Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation. Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug-drug interactions, and reduce systemically mediated adverse events. Compound 47 (PF-3635659) is identified as a Phase II clinical candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans.

[1]  M. Zaniboni,et al.  Bronchodilator Activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a Potent, Long-Acting, and Selective Muscarinic M3 Receptor Antagonist , 2010, Journal of Pharmacology and Experimental Therapeutics.

[2]  M. Bunnage,et al.  Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. , 2010, Journal of medicinal chemistry.

[3]  G. Joos.  Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease , 2010, Expert opinion on investigational drugs.

[4]  J. Magdalou,et al.  Insights on membrane topology and structure/function of UDP-glucuronosyltransferases , 2010, Drug metabolism reviews.

[5]  Dramane I. Laine,et al.  Long-acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease , 2010, Expert review of clinical pharmacology.

[6]  J. Cortijo,et al.  Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile , 2009, Journal of Pharmacology and Experimental Therapeutics.

[7]  M. Cazzola,et al.  Emerging inhaled bronchodilators: an update , 2009, European Respiratory Journal.

[8]  Zehong Wan,et al.  Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD. , 2009, Bioorganic & medicinal chemistry letters.

[9]  S. Sentellas,et al.  Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[ , 2009, Journal of medicinal chemistry.

[10]  P. Casarosa,et al.  Preclinical Evaluation of Long-Acting Muscarinic Antagonists: Comparison of Tiotropium and Investigational Drugs , 2009, Journal of Pharmacology and Experimental Therapeutics.

[11]  Zehong Wan,et al.  Design, synthesis, and structure-activity relationship of tropane muscarinic acetylcholine receptor antagonists. , 2009, Journal of medicinal chemistry.

[12]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[13]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2006, Nature Reviews Drug Discovery.

[14]  J. Bower,et al.  Cyclic sulfamidates as vehicles for the synthesis of substituted lactams. , 2004, Organic letters.

[15]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[16]  A. Fryer,et al.  Muscarinic acetylcholine receptors and airway diseases. , 2003, Pharmacology & therapeutics.

[17]  J. Miners,et al.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. , 2002, British journal of clinical pharmacology.

[18]  P. Barnes,et al.  Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. , 2002, Drugs of today.

[19]  Christine G. Espino,et al.  Synthesis of 1,3-Difunctionalized Amine Derivatives through Selective C−H Bond Oxidation , 2001 .

[20]  V. Alabaster.  Discovery & development of selective M 3 antagonists for clinical use , 1997 .

[21]  A. Taburet,et al.  Pharmacokinetic Optimisation of Asthma Treatment , 1994, Clinical pharmacokinetics.

[22]  R. A. Coleman,et al.  Investigations into factors determining the duration of action of the β2‐adrenoceptor agonist, salmeterol , 1993, British journal of pharmacology.

[23]  D. Roden,et al.  The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. , 1990, The New England journal of medicine.

[24]  N. Gross,et al.  Role of the parasympathetic system in airway obstruction due to emphysema. , 1984, The New England journal of medicine.

[25]  S. Denton.  A Modified Bouveault Reaction for the Preparation of α,α-Dimethylamines from Amides , 1999 .

[26]  B. Disse,et al.  Ba 679 BR, a novel long-acting anticholinergic bronchodilator. , 1993, Life sciences.